Is US Preparing For A Quademic 2025?

Updated Jan 15, 2025 | 03:10 PM IST

SummaryQuademic 2025: It is all caused by seasonal infections, including common flu, Covid-19, and respiratory syncytial virus (RSV) that dominate the winter season in the US. This year, norovirus also joined the list, which has further increased the load on the healthcare.
Is US preparing for a quademic?

Credits: Canva

Quademic 2025: Hospitals in the United States are dealing with a surge in patients admission, the reason is the quademic it is dealing with at this moment. This has led to an influx of patients. It is all caused by seasonal infections, including common flu, Covid-19, and respiratory syncytial virus (RSV) that dominate the winter season in the US. This year, norovirus also joined the list, which has further increased the load on the healthcare.

The healthcare company founded in academics M Health Fairview, confirmed that their hospitals are overflowing due to the quademic.

Is US able to cope with Quademic 2025?

The hospitals of M Health Fairview's volume is up by 30% and as a results, patients are being treated in the hallways and in alternative care areas. There is also a longer wait time and shortages for resources that are required to treat these emergencies. This has also impacted other life-threatening emergencies like heart attacks and strokes, as the healthcare resources and caregivers are occupied with the surge in seasonal cases.

ALSO READ: Birmingham Struggles With 4 Different Virus Hits, Know What They Are

What are these quademic infections?

Common cold and flu: The common cold and influenza (flu) are perhaps the most well-known illnesses that peak during the fall. As temperatures drop and humidity levels fluctuate, viruses that cause colds and the flu become more active. The flu, in particular, can be more severe than a common cold, leading to complications such as pneumonia, especially in vulnerable populations like the elderly and those with pre-existing health conditions. Symptoms include a runny nose, sore throat, coughing, fever, and body aches.

Covid-19: As per the World Health Organization, Coronavirus disease or COVID-19 is an infectious disease caused by the SARS-CoV-2 virus. Most people infected with this virus will experience mild to moderate respiratory illness and recover without requiring special treatment, However, there could be some cases of seriously ill patients who may require medical attention. It is also because of the other existing medical conditions like cardiovascular diseases, diabetes, chronic respiratory diseases, cancers, or older age.

The best way to protect against this virus is by following social isolation form those who are infected, using mask to prevent droplets from infecting others when you cough or sneeze and to wash your hands for 20 seconds frequently.

RSV or Respiratory Syncytial Virus: As per the Centers of Diseases Control and Prevention (CDC), RSV is a common respiratory virus that infects nose, throat and lungs. Though symptoms are similar to the viruses like flu or COVID-19, the disease in itself is different. It also peaks during the winter season, especially between December and January.

However, the main difference between RSV and other respiratory illness, above mentioned is that RSV can cause pneumonia or bronchiolitis, especially for those who are over the age of 50 or with an existing heart or lung disease.

Norovirus: It is a number 1 cause of foodborne illness in the US and this happens when virus gets into the food and then it accidentally enters your mouth. These particles are from faeces or vomit from infected people, or can be transmitted via contaminated food and water. It could also spread by touching unclean surfaces like door handles or cutlery.

For most people, having norovirus is unpleasant, but mild and recovery could be made in 1 to 2 days. However, it could be more serious for babies, older people and anyone with any existing health condition.

End of Article

Experimental Alzheimer's Drug Slows Cognitive Decline By 38% In A Two-Year Trial: How Does It Work?

Updated Nov 18, 2026 | 09:00 PM IST

SummaryBiogen's investigational Alzheimer's drug, injected 60 mg in the spinal cord, showed significant outcomes in slowing down cognitive decline linked with the disease.
Experimental Alzheimer's Drug Slows Cognitive Decline By 38% In A Two-Year Trial: How Does It Work?

Credit: AI image

There are currently no proven treatments to reverse Alzheimer’s but researchers are actively looking into treatments and therapies that could decrease the pace of disease progression and cognitive decline.

An experimental drug may be on the path to achieve that goal after it was able to slow cognitive decline by 38% over two years in people with early-stage Alzheimer’s. The development came to light after new clinical trial findings were announced by pharmaceutical company Biogen.

Experimental Alzheimer's Drug Slows Cognitive Decline

The experimental drug that targets a protein linked to Alzheimer's disease is called diranersen (BIIB080). It is equipped to reduce levels of tau, a protein that accumulates abnormally in the brains of people with Alzheimer's disease and causes damage to nerve cells.

Results from the Phase 2 CELIA trial, presented at the Clinical Trials on Alzheimer's Disease (CTAD) 2026 conference, showed that patients receiving the lowest dose of diranersen experienced more cognitive decline at two years than was reported at the 18-month assessment.

The 60 mg dose, administered through an injection into the fluid surrounding the spinal cord twice a year, slowed cognitive decline by 38% on the Clinical Dementia Rating-Sum of Boxes (CDR-SB) scale at 96 weeks. This was an improvement from the 26% slowing that was observed at 76 weeks.

The two-year results corresponded to a 1.09-point difference on the CDR-SB scale compared to the control group. The scale measures changes in memory, thinking abilities and the ability to do everyday activities.

Also read: 'Viagra For The Brain': New Pill Slows Decline in Memory, Thinking By 31% In Some Alzheimer's Patients

How Does The Investigational Alzheimer's Drug Work?

Tau is a protein that normally helps maintain the structure and stability of nerve cells. But, in Alzheimer's disease, tau can become abnormal, clump together and form structures known as neurofibrillary tangles inside brain cells.

They interfere with the normal functioning of nerve cells and can lead to progressive brain damage, memory loss and cognitive decline, symptoms usually seen in Alzheimer’s patients.

Diranersen belongs to a class of medicines that work by targeting genetic messages involved in producing proteins. In this case, diranersen targets the messenger RNA (mRNA) produced by the MAPT gene, which carries instructions for making tau protein. By targeting this genetic message, the drug aims to reduce the production of tau at source.

Recently approved Alzheimer's treatments like lecanemab and donanemab target amyloid-beta plaques, another abnormal protein accumulation associated with the disease. They work by helping the body clear amyloid deposits from the brain and have demonstrated modest slowing of cognitive decline in people with early Alzheimer's.

Diranersen works differently by targeting tau production rather than amyloid accumulation.

Also read: Older Adults Receiving High-Dose Flu Shots Show Lower Alzheimer's Risk: Study

Side Effects Of Diranersen

Biogen reported that diranersen was well tolerated over the two-year observation period as no new safety concerns came up.

Side effects mostly included headaches and back pain, which could have been due to lumbar puncture procedure used to administer the drug. A small number of participants also experienced confusion.

Unlike some existing Alzheimer's treatments, the trial did not report cases of amyloid-related brain swelling.

Diranersen is still undergoing clinical development and is not approved by the US Food and Drug Administration (FDA) or other regulatory authorities.

End of Article

India To Launch First Indigenous H5N1 Vaccine For Chickens As Bird Flu Cases Recur: How Can It Help?

Updated Nov 18, 2026 | 07:00 PM IST

SummaryScientists at ICAR-National Institute of High Security Animal Diseases (ICAR-NIHSAD), Bhopal developed India's first ever inactivated vaccine to immunise poultry and prevent bird flu.
India To Launch First Indigenous H5N1 Vaccine For Chickens As Bird Flu Cases Recur: How Can It Help?

Credit: AI

India is set to launch its first indigenously developed vaccine against H5N1 bird flu virus in chickens on November 20, as new outbreaks have been emerging in different parts of the country.

Developed by scientists at ICAR-National Institute of High Security Animal Diseases (ICAR-NIHSAD), the inactivated vaccine targets H5N1 Clade 2.3.2.1a, a strain that caused several bird flu outbreaks among chickens in India.

According to the Ministry of Agriculture and Farmers' Welfare, this marks a significant development in poultry and public health as there is no commercial vaccine against this particular H5N1 strain.

Why India Developed A Bird Flu Vaccine For Chickens?

Bird flu, medically known as avian influenza, is a viral infection that primarily affects birds. Highly pathogenic avian influenza (HPAI) strains, including H5N1, can cause severe illness and extremely high mortality among infected poultry.

Since the first detection of bird flu in India in 2006, the country has reported more than 500 combined outbreaks involving H5N1 and H5N8 subtypes.

These outbreaks can have serious economic consequences. Infected birds may need to be culled to prevent further transmission. The 2006 outbreak alone resulted in estimated direct and indirect losses of Rs 2,200–3,000 crore.

The newly developed vaccine can help strengthen the country’s ability to prevent outbreaks and protect poultry populations against the H5N1 strain currently circulating in the country.

Also read: UK Reports Its First Human Case Of Bird Flu

H5N1 Vaccine & Bird Flu Outbreaks In India

The indigenous vaccine contains an inactive version of the virus that cannot replicate and infect. When administered, it exposes the chicken's immune system to viral components, just enough to allow it to recognise the virus and develop an immune response.

If the vaccinated bird encounters the actual virus later, its immune system can recognise it and respond more effectively.

The vaccine announcement comes just as fresh reports of bird flu infections in poultry have emerged.

In Tamil Nadu's Cuddalore district, H5N1 infections were confirmed following sudden deaths among chickens at poultry farms. More than 35,000 birds had died by November 13, prompting authorities to initiate containment and culling efforts.

Andhra Pradesh has also reported H5N1 infections in poultry, prompting restrictions and surveillance measures.

The indigenous vaccine is an important step in India's poultry disease-control efforts, but its introduction does not mean bird flu outbreaks will be prevented completely.

Its effectiveness depends on vaccination coverage, administration, monitoring of viral strains and compliance with farm biosecurity measures.

Also read: New Strain Of Bird Flu Detected In US, Here’s How You Can To Stay Protected

Can Bird Flu Spread From Chickens To Humans?

Although H5N1 primarily affects birds, the virus can occasionally cross the zoonotic barrier and infect humans, especially those who have long-term contact with infected birds, their secretions or contaminated environments.

Human infections can cause symptoms ranging from mild respiratory illness to severe pneumonia and, in some cases, death.

According to the World Health Organization (WHO), 1,003 human cases of H5N1 infection, including 479 deaths, had been reported across 25 countries since 2003, as cited in the Indian government's November 18 announcement.

Human infections, however, remain relatively uncommon and sustained human-to-human transmission has not been established.

People working with poultry should avoid handling sick or dead birds without protective equipment. Unusual bird deaths should be reported to veterinary authorities.

End of Article

Lung Cancer Survival Improves By 71% In US: But 1 In 5 Patients Still Gets No Treatment

Updated Nov 18, 2026 | 06:00 PM IST

SummaryThe American Lung Association's annual report found that despite improved survival rates, 20.9% of lung cancer patients receive no treatment, only 29.3% are diagnosed early and just 24.4% of eligible people undergo screening.
Lung Cancer Survival Improves By 71% In US: But 1 In 5 Patients Still Gets No Treatment

Credit: iStock

Lung cancer remains the leading cause of cancer deaths in the US, with 229,410 new cases expected this year, according to a annual report from the American Lung Association's (ALA).

The Association's ninth annual State of Lung Cancer report stated that although five-year survival has improved, low screening rates, delayed diagnosis and unequal access to treatment remain major challenges.

Harold Wimmer, President and CEO of the ALA, said, “the national five-year survival rate has increased significantly, from 18.1% to 31.0%, and screening rates have also continued to rise.”

However, he warned that progress has not reached all communities equally.

“Awareness is still low and challenges remain. We must continue to drive progress on lung cancer screening, comprehensive biomarker testing, clinical trials and effective treatments to help people live longer, fuller lives after a lung cancer diagnosis.”

One In Five Lung Cancer Patients Receives No Treatment

Only 29.3% of lung cancer cases are diagnosed early. Rhode Island recorded the highest early diagnosis rate at 38%, while Hawaii had the lowest at 21.9%.

More concerning, 20.9% of patients received no treatment. The ALA identified potential barriers including lack of awareness, stigma, fatalism after diagnosis and treatment costs.

No-treatment rates ranged from 13.4% in Rhode Island to 36.7% in Nevada.

Only 1 In 4 Eligible People Gets Screened

Annual low-dose CT scans can detect lung cancer early in people at high risk. Yet only 24.4% of eligible Americans underwent screening.

Massachusetts recorded the highest screening rate at 38.7%, while South Dakota had the lowest at 13.5%.

Other Key Findings

  • The US is expected to record 229,410 new lung cancer cases this year, with an incidence rate of 52.1 per 100,000 people. Utah had the lowest rate (24.6), while Kentucky had the highest (83.9).
  • The five-year survival rate stands at 31%. Massachusetts recorded the highest rate (40.9%), while Alabama had the lowest (23.8%).
  • Only 21.4% of patients underwent surgery. Massachusetts had the highest surgical treatment rate (32.7%), while New Mexico had the lowest (12.7%).
  • Biomarker testing helps identify suitable targeted therapies and immunotherapies. Nineteen states mandate insurance coverage for comprehensive testing, seven require partial coverage, while 24 states and Washington, D.C., have no such mandate.
  • Racial disparities persist, with people of color less likely to receive early diagnoses or surgery and more likely to receive no treatment than white patients.

What Increases The Risk Of Lung Cancer?

Smoking is a major risk factor. Others include radon gas, air pollution and secondhand smoke. The ALA recommends radon testing, reducing air pollution and stronger tobacco-control measures, including smoke-free laws and access to smoking cessation services.

Why Is Lung Cancer Often Diagnosed Late?

Cleveland Clinic defines lung cancer as a malignant disease that happens when cells in the lung tissue grow out of control and form tumors. It is the leading cause of cancer deaths worldwide.

Lung cancer may cause no noticeable symptoms in its early stages. Symptoms can include persistent cough, coughing up blood, chest pain, unexplained weight loss, shortness of breath, recurrent chest infections and fatigue.

These symptoms should not be ignored. Early detection improves the chances of successful treatment, particularly before the cancer spreads.

End of Article